sysmex | Together for a better healthcare journey

Myeloid malignancy in focus

SureSeq™ NGS panels



The SureSeq™ NGS portfolio is growing! Check out two new panels that complement the next-generation sequencing solutions for haematological cancers.

High sensitivity
Optimised with guideline-led [1] content for myeloid MRD detection down to 0.01% VAF.

Enhanced detection of complex structural variants
SNVs, indels, ITDs, PTDs, CNVs, LOH and translocations.



Partner gene-agnostic
Enabling simultaneous detection of multiple breakpoints and fusions within a single assay.

Unlimited-use complimentary software
Highly configurable software according to your requirements. Locally installed or on the cloud.

SureSeq™ Myeloid Fusion Panel - Partner gene-agnostic fusion detection

- **RNA-based, partner gene-agnostic panel:** Detects 30 common myeloid fusions plus novel fusion partners in a single cost-efficient assay.
- **Developed in partnership with myeloid cancer experts in adherence with the latest WHO guidance [2]:** Combines expert-led panel design with hybridisation-based enrichment for unparalleled uniformity and depth of coverage.

SureSeq™ Myeloid MRD Panel - Measurable residual disease of myeloid samples down to 0.01% VAF

- **Class-leading sensitivity:** Designed to detect low-frequency variants with confidence, even for key AML MRD targets such as *NPM1* and *FLT3*-ITDs. Adjustable workflow for 0.1 or 0.01% VAF.
- **Designed in collaboration with leading cancer experts:** Detects SNVs and indels in 45 hotspot exons across 13 genes associated with accurate MRD detection in AML samples — including MDS and MPN implicated genes.

Investigator's feedback

"Overall, we were very happy with the promising results we obtained using the SureSeq™ Myeloid MRD Panel, which has led us to implement this panel for MRD analysis in our ongoing and planned clinical trials. In our hands this panel was able to detect all variants found by a comparator NGS Panel, generating no false positive calls, and most importantly, several additional clinically relevant variants, including *FLT3*-ITDs, that had not been detected by the comparator were found".

Prof Dr Klaus Metzeler
Attending Physician, Head of Diagnostics & Translational Research
Dept. of Haematology, Cell Therapy, Haemostaseology & Infectious Diseases
University of Leipzig Medical Center, Germany

References

[1] Heuser *et al.* Blood 2021; 138(26): 2753–2767
[2] Khoury *et al.* Leukemia. 2022 ; 36:1703-19.

Consult your Sysmex representative and inquire about other SureSeq™ haematological malignancy NGS panels – **SureSeq™ Core MPN Panel, SureSeq™ Pan-Myeloid Panel, SureSeq™ Myeloid Plus Panel, and SureSeq™ CLL + CNV V3 Panel**

Distributor EMEA: Sysmex Europe SE · www.sysmex-europe.com
Manufacturer SureSeq™: OGT · www.ogt.com
You will find your local Sysmex representative's address under www.sysmex-europe.com/contacts

www.sysmex-europe.com/sureseq

EN.N.05/25